Loading the records…
Loading the records…

Daniel Meuser (R-PA) sold $250K-$500K of $NVDA (NVIDIA Corporation - Common Stock) on Feb 11, 2025, part of 9 transactions in this filing.
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| PARTIAL SELL | $NVDA | NVIDIA Corporation - Common Stock | $250K-$500K | $132.80 | — | — | Feb 11, 2025 |
| SELL | $GOOGL | Alphabet Inc. - Class A Common Stock | $50K-$100K | $185.32 | — | — | Feb 11, 2025 |
| SELL | $AAPL | Apple Inc. - Common Stock | $15K-$50K | $232.62 | — | — | Feb 11, 2025 |
| SELL | $QCOM | QUALCOMM Incorporated - Common Stock | $15K-$50K | $171.99 | — | — | Feb 11, 2025 |
| SELL | $V | Visa Inc. | $15K-$50K | $350.72 | — | — | Feb 11, 2025 |
| SELL | $AMGN | Amgen Inc. - Common Stock | $1K-$15K | $296.66 | — | — | Feb 11, 2025 |
| SELL | $APTV | Aptiv PLC Ordinary Shares | $1K-$15K | $64.66 | — | — | Feb 11, 2025 |
| SELL | $MSFT | Microsoft Corporation - Common Stock | $1K-$15K | $411.44 | — | — | Feb 11, 2025 |
| SELL | $MDLZ | Mondelez International, Inc. - Class A Common Stock | $1K-$15K | $60.45 | — | — | Feb 11, 2025 |
These bills and contracts share tickers or sectors with this filing's trades.
The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.
HR910 is a diplomatic bill requiring the U.S. Treasury to advocate for Taiwan's equitable treatment at the IMF. It authorizes zero funding, imposes no mandatory regulations on U.S. companies, and has no direct market impact on any publicly traded entity. The bill is procedural in nature—directing U.S. votes within an international institution—and carries no binding economic mechanisms for U.S. firms.
The MAPWaters Act, with a companion bill already signed into law (HR187 → PL 119-62), mandates federal agencies to standardize geospatial waterway data. Trimble ($TRMB) is the primary pure-play beneficiary. The stock is at $66.84, near the bottom of its 52-week range ($62–$87.5), offering a potential entry point if procurement contracts materialize. No funding is authorized directly, so revenue depends on agency procurement budgets.
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
The Price Gouging Prevention Act of 2025 (HR4528) is an early-stage House bill capping corporate margins during 'exceptional market shocks'. Currently referred to committee with zero appropriations, the bill poses a structural long-term regulatory risk to all large-cap companies with pricing flexibility, particularly retailers ($WMT, $AMZN) and integrated energy ($XOM, $CVX). Near-term market impact is low given early legislative stage, but the bill's breadth — covering all goods and services — represents a significant expansion of FTC authority if it advances.
S.2367 introduces a broad federal tort for personal data exploitation without express consent, directly targeting the data practices underlying AI training and advertising at META, GOOGL, AMZN, MSFT, and CRM. The bill is early-stage (introduced July 2025, referred to Judiciary Committee), but its language is aggressive and unambiguous. Current market prices show a sharp 1-day drop for META (-8.72% 7-day) and GOOGL at an all-time high of $373.96 — divergence suggests GOOGL's run is driven by other factors, not immunity from this risk.
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
HR4548 opens the tax-exempt small employer market (1.3M 501(c) organizations) to retirement plan subsidies for the first time, creating a new customer acquisition opportunity for payroll and retirement administration providers ADP and PAYX. The bill is in early legislative stages with bipartisan sponsorship.
The Blue Shield Privacy Act of 2025 (HR4828) is an early-stage House bill that expands the definition of 'restricted personal information' under federal criminal law to include biometric data, GPS coordinates, license plates, and workplace/school addresses. At referral to the House Judiciary Committee only, with 7 cosponsors and no markup or hearings yet, the bill has no near-term market impact. Real market data show GOOGL at $368.29 (up 6.94% over 7 days, up 28.07% over 30 days), META at $600.42 (down 11.05% over 7 days), AMZN at $258.48 (down 2.09% over 7 days), and MSFT at $400.59 (down 5.66% over 7 days) — these price movements are driven by other factors, not this procedural bill.
The STOP CSAM Act (S.1829) has advanced to the Senate calendar, increasing passage probability. The bill mandates elevated content moderation and reporting requirements for major tech and telecom companies, directly increasing compliance costs. Affected tickers include $META, $GOOGL, $MSFT, $AMZN, $VZ, $T, and $TWLO. Market data shows strong recent rallies in tech stocks ($GOOGL +27.95%, $META +24.75%, $AMZN +30.9% over 30 days), creating potential downside risk if compliance cost headwinds materialize.
Free — no credit card
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.